Gilead Sciences (GILD) News Today

Gilead Sciences, Inc. (NASDAQ:GILD) saw its stock rise following a series of strong Q2 results, analyst upgrades and shareholder-friendly actions.

• Positive Sentiment: Gilead topped Q2 earnings and revenue forecasts—$2.01 EPS vs. $1.96 consensus and $7.08 B sales vs. $6.95 B estimate—and raised its full-year outlook on robust HIV and oncology drug demand. Reuters
• Positive Sentiment: Bank of America boosted its GILD price target to $140 (from $126), citing sustained growth in core franchises. Investing.com
• Positive Sentiment: Truist Financial upgraded Gilead from “hold” to “buy” and lifted its target to $127 (from $108), pointing to upside potential. Benzinga
• Positive Sentiment: Gilead declared a $0.79 quarterly dividend and launched a $6 billion share buyback program, enhancing shareholder returns. Seeking Alpha
• Positive Sentiment: FDA approval and imminent launch of Yeztugo were highlighted as catalysts for expanded market share and cash-flow stability. Benzinga
• Neutral Sentiment: Barron’s flagged Gilead as one of the biggest stock movers early Friday after its Q2 beat. Barron’s
• Neutral Sentiment: Q2 2025 earnings call transcript is available for detailed review. Seeking Alpha
• Neutral Sentiment: Zacks published an analysis of GILD’s key Q2 metrics vs. estimates. Zacks
• Negative Sentiment: RBC kept Gilead at “sector perform” despite raising its target from $96 to $98, implying nearly an 18% downside. Benzinga
• Negative Sentiment: UBS maintained a “neutral” rating even after lifting its target to $112, signaling about a 6% potential pullback. Benzinga

In sum, Gilead’s robust Q2 results and upgraded guidance spurred bullish analyst moves and supported the share uptick, although some firms remain cautious with targets below current levels.